Keywords

• Fast delivery of Doravirine (MK-1439)
• High purity of Doravirine (MK-1439)
• Lower price of Doravirine (MK-1439)

Quick Details

• ProName: Doravirine (MK-1439)
• CasNo: 1338225-97-0
• Application: Doravirine (MK-1439) is a non-nucleosi...
• DeliveryTime: immediate shipment
• PackAge: carton or drum
• Port: Shanghai
• ProductionCapacity: 500 Kilogram/Day
• Purity: 99%
• Storage: store in tight conianter with lower te...
• Transportation: by air or by express
• LimitNum: 1 Gram

Superiority

Chemvon Biotechnology is one of the leading high-technology manufacturer in the field of pharmaceutical and fine chemical industry.

From origins as a research group in technology service, chemvon has progressed into an integrated company with a kilo lab and a pilot plant offering a range of APIs, NCEs and some organic intermediates.

Quality: Adopting the leading technology to assure the high quality.

Price: Offering the best price among the suppliers in China.

Rich material and energe make us control the cost effective

Afrer-sale service: Chemvon will take charge of everthing if there is any question after the sale.

Certificates: We can offer ISO9001 certificates that you need for importing.

Product name: Doravirine (MK-1439)

Cas no: 1338225-97-0

Superiority: high quality and lower price

We are manufacturer

Transportation: by express,by air,by sea

Details

Product name: Doravirine ( MK-1439)

Purity:  99% min

Synonym: MK-1439

CAS NO.: 1338225-97-0

Molecular Formula: Doravirine ( MK-1439) has the molecular formula being C17H11ClF3N5O3

Molecular weight: Doravirine ( MK-1439) has the molecular weight being 425.7491496

Product quality: our professional technicians have studied the characteristic specifications of   Doravirine ( MK-1439)(1338225-97-0 ), including appearance, identification, assay, related substances, residual solvents and so on. For more detailed COA, please contact us. Email: marketing@chemvon.com

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor,for use in the treatment of HIV/AIDS. Doravirine demonstrated robust antiviral activity and good tolerability in a small clinical study of 7-day monotherapy reported at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013. Doravirine appeared safe and generally well-tolerated with most adverse events being mild-to-moderate